Peritoneal dialysis solutions low in glucose degradation products-evidence for clinical benefits

Peritoneal Dialysis International

Volumn 28, Issue SUPP. 3, 2008, Pages

  Tomo, Tadashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

3,4 DGE; 3,4 dideoxyglucosone 3 ene; Combination therapy; GDPs; Glucose degradation products; PD HD combination therapy

Indexed keywords

3,4 DIDEOXYGLUCOSONE 3 ENE; ADVANCED GLYCATION END PRODUCT; GLUCOSE DEGRADATION PRODUCT; ICODEXTRIN; PERITONEAL DIALYSIS FLUID;

BIOCOMPATIBILITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; GLUCOSE BLOOD LEVEL; GLYCATION; HEMODIALYSIS; HUMAN; HUMAN CELL; KIDNEY FUNCTION; LONG TERM EXPOSURE; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL; REST; THERAPY EFFECT; TREATMENT RESPONSE; VASCULAR PATENCY;

COMBINED MODALITY THERAPY; DIALYSIS SOLUTIONS; GLUCOSE; HEMODIAFILTRATION; HUMANS; JAPAN; PERITONEAL DIALYSIS; PERITONEAL DISEASES; PERITONEUM; PYRONES; TREATMENT OUTCOME;

EID: 48749130657     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-39.
2. Di Paolo N, Garosi G, Traversari L, Di Paolo M. Mesothelial biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1993; 13(Suppl 2):S109-12.
3. Breborowicz A, Rodela H, Karon J, Martis L, Oreopoulos DG. In vitro simulation of the effect of peritoneal dialysis solution on mesothelial cells. Am J Kidney Dis 1997; 29:404-9.
4. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
5. Lage C, Pischetsrieder M, Aufricht C, Jörres A, Schilling H, Passlick-Deetjen J. First in vitro and in vivo experiences with Stay·Safe Balance, a pH-neutral solution in a dual-chambered bag. Perit Dial Int 2000; 20(Suppl 5):S28-32.
6. Topley N, Kaur D, Petersen MM, Jörres A, Passlick-Deetjen J, Coles GA, et al. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int 1996; 49:1447-56.
7. Witowski J, Topley N, Jörres A, Liberek T, Coles GA, Williams JD. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995; 47:282-93.
8. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A. 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002; 62:697-703.
9. Tomo T, Okabe E, Yamamoto T, Namoto S, Iwashita T, Matsuyama K, et al. Impact of 3,4-dideoxyglucosone-3-ene (3,4-DGE) on cytotoxicity of acidic heat-sterilized peritoneal dialysis fluid. J Artif Organs 2007; 10:47-51.
10. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63:298-305.
11. Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, et al. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 2007; 22:2038-44.
12. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998; 9:2349-56.
13. Rashid G, Benchetrit S, Fishman D, Bernheim J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int 2004; 66:1099-106.
14. Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR, et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21:2893-9.
15. de Alvaro F, Castro MJ, Dapena F, Bajo MA, Fernandez-Reyes MJ, Romero JR, et al. Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 1993; 9:56-61.
16. Kawanishi H, Moriishi M, Katsutani S, Sakikubo E, Tsuchiya S. Hemodialysis together with peritoneal dialysis is one of the simplest ways to maintain adequacy in continuous ambulatory peritoneal dialysis. Adv Perit Dial 1999; 15:127-31.
17. Kawanishi H, Moriishi M, Tsuchiya S. Five years' experience of combination therapy: peritoneal dialysis with hemodialysis. Adv Perit Dial 2002; 18:62-7.
18. Fukui H, Hara S, Hashimoto Y, Horiuchi T, Ikezoe M, Itami N, et al. Review of combination of peritoneal dialysis and hemodialysis as a modality of treatment for end-stage renal disease. Ther Apher Dial 2004; 8:56-61.
19. Agarwal M, Clinard P, Burkart JM. Combined peritoneal dialysis and hemodialysis: our experience compared to others. Perit Dial Int 2003; 23:157-61.
20. Tomo T, Okabe E, Matsuyama K, Iwashita T, Yufu K, Nasu M. The effect of peritoneal rest in combination therapy of peritoneal dialysis and hemodialysis: using the cultured human peritoneal mesothelial cell model. J Artif Organs 2005; 8:125-9.